Table 2.
Proportions of participants achieving hSBA titers ≥1:8 at baseline (Day 0) and at Day 30 post-vaccination against serogroups A, C, W, and Y by vaccine group (PPAS).
| MenACYW-TT, % (95% CI) |
MPSV4, % (95% CI) |
||||||
|---|---|---|---|---|---|---|---|
| Serogroup | Total | 56–64 y | ≥65 y | Total | 56–64 y | ≥65 y | |
| N | 195 | 98 | 97 | 94 | 46 | 48 | |
| A | Day 0 | 76.4 (69.8, 82.2) | 79.6 (70.3, 87.1) | 73.2 (63.2, 81.7) | 79.8 (70.2, 87.4) | 82.6 (68.6, 92.2) | 77.1 (62.7, 88.0) |
| Day 30 | 93.8 (89.5, 96.8) | 95.9 (89.9, 98.9) | 91.8 (84.4, 96.4) | 85.1 (76.3, 91.6) | 78.3 (63.6, 89.1) | 91.7 (80.0, 97.7) | |
| C | Day 0 | 17.4 (12.4, 23.5) | 16.3 (9.6, 25.2) | 18.6 (11.4, 27.7) | 10.6 (5.2, 18.7) | 13.0 (4.9, 26.3) | 8.3 (2.3, 20.0) |
| Day 30 | 74.9 (68.2, 80.8) | 71.4 (61.4, 80.1) | 78.4 (68.8, 86.1) | 62.8 (52.2, 72.5) | 58.7 (43.2, 73.0) | 66.7 (51.6, 79.6) | |
| W | Day 0 | 13.3 (8.9, 18.9) | 15.3 (8.8, 24.0) | 11.3 (5.8, 19.4) | 8.5 (3.7, 16.1) | 8.7 (2.4, 20.8) | 8.3 (2.3, 20.0) |
| Day 30 | 79.5 (73.1, 84.9) | 77.6 (68.0, 85.4) | 81.4 (72.3, 88.6) | 60.6 (50.0, 70.6) | 58.7 (43.2, 73.0) | 62.5 (47.4, 76.0) | |
| Y | Day 0 | 13.3 (8.9, 18.9) | 12.2 (6.5, 20.4) | 14.4 (8.1, 23.0) | 24.5 (16.2, 34.4) | 17.4 (7.8, 31.4) | 31.3 (18.7, 46.3) |
| Day 30 | 80.5 (74.2, 85.8) | 81.6 (72.5, 88.7) | 79.4 (70.0, 86.9) | 59.6 (49.0, 69.6) | 60.9 (45.4, 74.9) | 58.3 (43.2, 72.4) | |